Influenza A H1N1 Hemagglutinin
/ HA抗体 | Influenza A H1N1 Hemagglutinin / HA Polyclonal Antibody- 询价
- 辰辉创聚生物
- 中国
- NBAB-106474
- 2025年07月12日
- WB; ELISA
- IHC, FCM, IF, IP et al. applications haven't been validated. (Antibody's applications haven't been validated with corresponding virus positive samples. Optimal concentrations/dilutions should be determined by the end user.)
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant H1N1 HA Protein
- 亚型：
Polyclonal Rabbit IgG
- 保存条件：
This liquid antibody can be stored at 2℃-6356℃ for at least two weeks. Avoid repeated freeze/thaw cycles.
- 克隆性：
多克隆
- 适应物种：
IHC, FCM, IF, IP et al. applications haven't been validated. (Antibody's applications haven't been validated with corresponding virus positive samples. Optimal concentrations/dilutions should be determined by the end user.)
- 保质期：
see COA
- 库存：
大量
- 供应商：
辰辉创聚生物
- 应用范围：
WB; ELISA
- 靶点：
Influenza A H1N1 Hemagglutinin / HA
- 抗体英文名：
Influenza A H1N1 Hemagglutinin / HA antibody
- 抗体名：
Influenza A H1N1 Hemagglutinin / HA抗体
- 规格：
100ug;500ug;1mg
| 产品信息
品名:NebuSelect™ Influenza A H1N1 Hemagglutinin / HA Polyclonal Antibody
货号:NBAB-106474
品牌:Nebulabio
规格:100ug;500ug;1mg
| 产品描述
| 产品属性
Product Category：Rabbit PAb
Reactivity：IHC, FCM, IF, IP et al. applications haven't been validated. (Antibody's applications haven't been validated with corresponding virus positive samples. Optimal concentrations/dilutions should be determined by the end user.)
Specificity：H1N1 (A/Puerto Rico/8/1934) HA
Immunogen：Recombinant H1N1 HA Protein
Isotype：Polyclonal Rabbit IgG
Purification：Protein A
Buffer：0.2 μm filtered solution in PBS
Conjugate：Unconjugated
Applications：WB; ELISA
Dilution：
Storage：Store at 4°C for short-term, -20°C for long-term. Avoid repeated freezing and thawing cycles.
For Research Use Only!
To get more information, please contact us freely.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验PCR for the Detection of Influenza Viruses in Clinical Material
). Influenza A viruses are further divided into subtypes H1N1, H2N2 and H3N2, based on differences in the hemagglutinin (HA) and neuraminidase (NA) genes. The ability of influenza viruses to undergo antigenic change in HA and NA enables the virus to evade
Genetic Engineering of Live Attenuated Influenza Viruses
The first live attenuated influenza vaccine (LAIV) was licensed in the USA in 2003; it is a trivalent vaccine composed of two type A (H1N1 and H3N2) and one type B influenza virus each at 107 fluorescent focus units (FFU). Each influenza
The Mouse as Model System to Study Host‐Pathogen Interactions in Influenza A Infections
. Sun, X., Tse, L.V., Ferguson, A.D., and Whittaker, G.R. 2010. Modifications to the hemagglutinin cleavage site control the virulence of a neurotropic H1N1 influenza virus. J. Virol. 84:8683‐8690
技术资料暂无技术资料 索取技术资料
